{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:25:47Z","timestamp":1790267147025,"version":"4.1.0"},"reference-count":74,"publisher":"Bioscientifica","issue":"2","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":3913,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Over the past decades, the incidence of differentiated thyroid carcinoma (DTC) has steadily increased, with especially a growing number of low-risk patients. Whereas DTC used to be treated rather aggressively, it is now acknowledged that aggressive treatment does not affect outcome for low-risk patients and that it can induce adverse effects. In this review an overview of the most clinically relevant adverse effects of radioiodine treatment and thyroid hormone suppression therapy (THST) is presented, and the trend toward less aggressive treatment for low-risk patients is outlined. Salivary gland dysfunction occurs in roughly 30% of patients, and is probably due to the concentration of radioiodine in the salivary glands by the sodium\/iodide symporter. Beta radiation from radioiodine can result in sialoadenitis and eventually fibrosis and loss of salivary function. Furthermore, patients can experience bone marrow dysfunction following radioiodine treatment. Although this is in general subclinical and transient, patients that receive very high cumulative radioiodine doses may be at risk for more severe bone marrow dysfunction. THST can induce adverse cardiovascular effects in patients with DTC, such as diastolic and systolic dysfunction, and also adverse vascular and prothrombotic effects have been described. Finally, the effects of THST on bone formation and resorption are outlined; especially postmenopausal women with DTC on THST seem to be at risk of bone loss. In the past years, advances have been made in preventing low-risk patients from being overtreated. Improved biomarkers are still needed to further optimize risk stratification and personalize medicine.<\/jats:p>","DOI":"10.1159\/000432397","type":"journal-article","created":{"date-parts":[[2015,6,11]],"date-time":"2015-06-11T21:43:31Z","timestamp":1434059011000},"page":"82-92","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":24,"title":["Radioiodine Treatment and Thyroid Hormone Suppression Therapy for Differentiated Thyroid Carcinoma: Adverse Effects Support the Trend toward Less Aggressive Treatment for Low-Risk Patients"],"prefix":"10.1530","volume":"4","author":[{"given":"E.N.","family":"Klein Hesselink","sequence":"first","affiliation":[{"name":"1Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.P.","family":"Links","sequence":"additional","affiliation":[{"name":"1Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2015,6,11]]},"reference":[{"key":"2026070712454808900_ref1","doi-asserted-by":"crossref","unstructured":"DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A: Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014;64:252-271.10.3322\/caac.2123524890451","DOI":"10.3322\/caac.21235"},{"key":"2026070712454808900_ref2","doi-asserted-by":"crossref","unstructured":"Ahn HS, Kim HJ, Welch HG: Korea's thyroid-cancer \u2018epidemic '- screening and overdiagnosis. N Engl J Med 2014;371:1765-1767.10.1056\/NEJMp140984125372084","DOI":"10.1056\/NEJMp1409841"},{"key":"2026070712454808900_ref3","doi-asserted-by":"crossref","unstructured":"Hyer SL, Newbold K, Harmer CL: Early and late toxicity of radioiodine therapy: detection and management. Endocr Pract 2010;16:1064-1070.10.4158\/EP10170.RA20634173","DOI":"10.4158\/EP10170.RA"},{"key":"2026070712454808900_ref4","doi-asserted-by":"crossref","unstructured":"Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI: Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16:1229-1242.10.1089\/thy.2006.16.122917199433","DOI":"10.1089\/thy.2006.16.1229"},{"key":"2026070712454808900_ref5","doi-asserted-by":"crossref","unstructured":"van Nostrand D: Sialoadenitis secondary to 131I therapy for well-differentiated thyroid cancer. Oral Dis 2011;17:154-161.10.1111\/j.1601-0825.2010.01726.x21029259","DOI":"10.1111\/j.1601-0825.2010.01726.x"},{"key":"2026070712454808900_ref6","doi-asserted-by":"crossref","unstructured":"La Perle KM, Kim DC, Hall NC, Bobbey A, Shen DH, Nagy RS, Wakely PE Jr, Lehman A, Jarjoura D, Jhiang SM: Modulation of sodium\/iodide symporter expression in the salivary gland. Thyroid 2013;23:1029-1036.10.1089\/thy.2012.057123441638","DOI":"10.1089\/thy.2012.0571"},{"key":"2026070712454808900_ref7","doi-asserted-by":"crossref","unstructured":"Spitzweg C, Joba W, Schriever K, Goellner JR, Morris JC, Heufelder AE: Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. J Clin Endocrinol Metab 1999;84:4178-4184.10.1210\/jcem.84.11.611710566669","DOI":"10.1210\/jc.84.11.4178"},{"key":"2026070712454808900_ref8","doi-asserted-by":"crossref","unstructured":"Mandel SJ, Mandel L: Radioactive iodine and the salivary glands. Thyroid 2003;13:265-271.10.1089\/10507250332158206012729475","DOI":"10.1089\/105072503321582060"},{"key":"2026070712454808900_ref9","doi-asserted-by":"crossref","unstructured":"Mandel L: Hyposalivation: the roles of radioactive iodine and stapes surgery. J Oral Maxillofac Surg 2013;71:e76-e80.10.1016\/j.joms.2012.09.01823351771","DOI":"10.1016\/j.joms.2012.09.018"},{"key":"2026070712454808900_ref10","doi-asserted-by":"crossref","unstructured":"Pringle S, van Os R, Coppes RP: Concise review: adult salivary gland stem cells and a potential therapy for xerostomia. Stem Cells 2013;31:613-619.10.1002\/stem.132723335219","DOI":"10.1002\/stem.1327"},{"key":"2026070712454808900_ref11","doi-asserted-by":"crossref","unstructured":"Vissink A, Mitchell JB, Baum BJ, Limesand KH, Jensen SB, Fox PC, Elting LS, Langendijk JA, Coppes RP, Reyland ME: Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers. Int J Radiat Oncol Biol Phys 2010;78:983-991.10.1016\/j.ijrobp.2010.06.05220970030","DOI":"10.1016\/j.ijrobp.2010.06.052"},{"key":"2026070712454808900_ref12","doi-asserted-by":"crossref","unstructured":"Walter MA, Turtschi CP, Schindler C, Minnig P, Muller-Brand J, Muller B: The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study. J Nucl Med 2007;48:1620-1625.10.2967\/jnumed.107.04219217873131","DOI":"10.2967\/jnumed.107.042192"},{"key":"2026070712454808900_ref13","doi-asserted-by":"crossref","unstructured":"Hyer S, Kong A, Pratt B, Harmer C: Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol (R Coll Radiol) 2007;19:83-86.10.1016\/j.clon.2006.11.00517305259","DOI":"10.1016\/j.clon.2006.11.005"},{"key":"2026070712454808900_ref14","unstructured":"Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM: Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998;39:1551-1554.9744341"},{"key":"2026070712454808900_ref15","unstructured":"Solans R, Bosch JA, Galofre P, Porta F, Rosello J, Selva-O'Callagan A, Vilardell M: Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 2001;42:738-743.11337569"},{"key":"2026070712454808900_ref16","doi-asserted-by":"crossref","unstructured":"de Luca R, Vicidomini A, Trodella M, Tartaro G, Colella G: Sialoendoscopy: A viable treatment for I131 induced sialoadenitis. Br J Oral Maxillofac Surg 2014;52:641-646.10.1016\/j.bjoms.2014.01.02524894709","DOI":"10.1016\/j.bjoms.2014.01.025"},{"key":"2026070712454808900_ref17","unstructured":"Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, Zhao S, Tamaki N, Noguchi Y, Noguchi S: Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 2005;46:261-266.15695785"},{"key":"2026070712454808900_ref18","doi-asserted-by":"crossref","unstructured":"Jentzen W, Balschuweit D, Schmitz J, Freudenberg L, Eising E, Hilbel T, Bockisch A, Stahl A: The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(\/CT) imaging. Eur J Nucl Med Mol Imaging 2010;37:2298-2306.10.1007\/s00259-010-1532-z20625723","DOI":"10.1007\/s00259-010-1532-z"},{"key":"2026070712454808900_ref19","doi-asserted-by":"crossref","unstructured":"van Nostrand D, Atkins F, Bandaru VV, Chennupati SP, Moreau S, Burman K, Wartofsky L: Salivary gland protection with sialagogues: a case study. Thyroid 2009;19:1005-1008.10.1089\/thy.2008.038119500022","DOI":"10.1089\/thy.2008.0381"},{"key":"2026070712454808900_ref20","doi-asserted-by":"crossref","unstructured":"Kulkarni K, van Nostrand D, Atkins F, Mete M, Wexler J, Wartofsky L: Does lemon juice increase radioiodine reaccumulation within the parotid glands more than if lemon juice is not administered? Nucl Med Commun 2014;35:210-216.10.1097\/MNM.000000000000003424177041","DOI":"10.1097\/MNM.0000000000000034"},{"key":"2026070712454808900_ref21","doi-asserted-by":"crossref","unstructured":"Silberstein EB: Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine. J Nucl Med 2008;49:546-549.10.2967\/jnumed.107.04941118344428","DOI":"10.2967\/jnumed.107.049411"},{"key":"2026070712454808900_ref22","doi-asserted-by":"crossref","unstructured":"Kim SJ, Choi HY, Kim IJ, Kim YK, Jun S, Nam HY, Kim JS: Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients: analysis of quantitative salivary scan. Thyroid 2008;18:325-331.10.1089\/thy.2007.019118341378","DOI":"10.1089\/thy.2007.0191"},{"key":"2026070712454808900_ref23","doi-asserted-by":"crossref","unstructured":"Rosario PW, Calsolari MR: Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin. Thyroid 2013;23:617-619.10.1089\/thy.2012.005023136908","DOI":"10.1089\/thy.2012.0050"},{"key":"2026070712454808900_ref24","doi-asserted-by":"crossref","unstructured":"Tofani A, Sciuto R, Cioffi RP, Pasqualoni R, Rea S, Festa A, Gandolfo GM, Arista MC, Maini CL: Radioiodine-induced changes in lymphocyte subsets in patients with differentiated thyroid carcinoma. Eur J Nucl Med 1999;26:824-829.10.1007\/s00259005045510436194","DOI":"10.1007\/s002590050455"},{"key":"2026070712454808900_ref25","unstructured":"Haynie TP, Beierwaltes WH: Hematologic changes observed following I-131 therapy for thyroid carcinoma. J Nucl Med 1963;4:85-91.13963594"},{"key":"2026070712454808900_ref26","doi-asserted-by":"crossref","unstructured":"Keldsen N, Mortensen BT, Hansen HS: Haematological effects from radioiodine treatment of thyroid carcinoma. Acta Oncol 1990;29:1035-1039.10.3109\/028418690090917962278724","DOI":"10.3109\/02841869009091796"},{"key":"2026070712454808900_ref27","unstructured":"Menzel C, Grunwald F, Schomburg A, Palmedo H, Bender H, Spath G, Biersack HJ: \u2018High-dose' radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med 1996;37:1496-1503.8790201"},{"key":"2026070712454808900_ref28","doi-asserted-by":"crossref","unstructured":"Petrich T, Widjaja A, Musholt TJ, Hofmann M, Brunkhorst T, Ehrenheim C, Oetting G, Knapp WH: Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age. Eur J Nucl Med 2001;28:203-208.10.1007\/s00259000042011303891","DOI":"10.1007\/s002590000420"},{"key":"2026070712454808900_ref29","unstructured":"Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K, Larson SM, Chan CY: Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 2006;47:1587-1591.17015892"},{"key":"2026070712454808900_ref30","doi-asserted-by":"crossref","unstructured":"Padovani RP, Tuttle RM, Grewal R, Larson SM, Boucai L: Complete blood counts are frequently abnormal 1 year after dosimetry-guided radioactive iodine therapy for metastatic thyroid cancer. Endocr Pract 2014;20:213-220.10.4158\/EP13172.OR24126230","DOI":"10.4158\/EP13172.OR"},{"key":"2026070712454808900_ref31","doi-asserted-by":"crossref","unstructured":"Taieb D, Sebag F, Farman-Ara B, Portal T, Baumstarck-Barrau K, Fortanier C, Bourrelly M, Mancini J, De Micco C, Auquier P, Conte-Devolx B, Henry JF, Mundler O: Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal. J Clin Endocrinol Metab 2010;95:3283-3290.10.1210\/jc.2009-252820392868","DOI":"10.1210\/jc.2009-2528"},{"key":"2026070712454808900_ref32","doi-asserted-by":"crossref","unstructured":"Amdur RJ, Dan T, Mazzaferri E: Absence of bone marrow toxicity in elderly patients treated with recombinant human thyroid-stimulating hormone and empirically dosed radioiodine for thyroid cancer. Am J Clin Oncol 2013;36:348-353.10.1097\/COC.0b013e318248d67c22547013","DOI":"10.1097\/COC.0b013e318248d67c"},{"key":"2026070712454808900_ref33","doi-asserted-by":"crossref","unstructured":"Molinaro E, Leboeuf R, Shue B, Martorella AJ, Fleisher M, Larson S, Tuttle RM: Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation. Thyroid 2009;19:1035-1041.10.1089\/thy.2008.043019772430","DOI":"10.1089\/thy.2008.0430"},{"key":"2026070712454808900_ref34","unstructured":"Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA: Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med 2003;44:451-456.12621014"},{"key":"2026070712454808900_ref35","doi-asserted-by":"crossref","unstructured":"Freesmeyer M: A severe haematologic adverse reaction after high dosage radioiodine therapy following blood stem cell mobilization with growth factors. Nuklearmedizin 2011;50:N34-N36.21833439","DOI":"10.1055\/s-0037-1621656"},{"key":"2026070712454808900_ref36","unstructured":"Mazzaferri EL: Papillary and follicular thyroid cancer: selective therapy. Compr Ther 1981;7:6-14.7016424"},{"key":"2026070712454808900_ref37","doi-asserted-by":"crossref","unstructured":"Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD: The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid 2010;20:1235-1245.10.1089\/thy.2009.045521062195","DOI":"10.1089\/thy.2009.0455"},{"key":"2026070712454808900_ref38","doi-asserted-by":"crossref","unstructured":"Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, Bardet S, Leenhardt L, Bastie D, Schvartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Dejax C, Toubert ME, Leboulleux S, Ricard M, Benhamou E, et al: Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med 2012;366:1663-1673.10.1056\/NEJMoa110858622551127","DOI":"10.1056\/NEJMoa1108586"},{"key":"2026070712454808900_ref39","doi-asserted-by":"crossref","unstructured":"Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, et al: Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med 2012;366:1674-1685.10.1056\/NEJMoa110958922551128","DOI":"10.1056\/NEJMoa1109589"},{"key":"2026070712454808900_ref40","doi-asserted-by":"crossref","unstructured":"Kukulska A, Krajewska J, Gawkowska-Suwinska M, Puch Z, Paliczka-Cieslik E, Roskosz J, Handkiewicz-Junak D, Jarzab M, Gubala E, Jarzab B: Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi. Thyroid Res 2010;3:9.10.1186\/1756-6614-3-921040579","DOI":"10.1186\/1756-6614-3-9"},{"key":"2026070712454808900_ref41","doi-asserted-by":"crossref","unstructured":"Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2009;19:1167-1214.10.1089\/thy.2009.011019860577","DOI":"10.1089\/thy.2009.0110"},{"key":"2026070712454808900_ref42","doi-asserted-by":"crossref","unstructured":"Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, European Thyroid Cancer Taskforce: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803.10.1530\/eje.1.0215816728537","DOI":"10.1530\/eje.1.02158"},{"key":"2026070712454808900_ref43","doi-asserted-by":"crossref","unstructured":"Klein I, Ojamaa K: Thyroid hormone and the cardiovascular system. N Engl J Med 2001;344:501-509.10.1056\/NEJM20010215344070711172193","DOI":"10.1056\/NEJM200102153440707"},{"key":"2026070712454808900_ref44","doi-asserted-by":"crossref","unstructured":"Klein I, Danzi S: Thyroid disease and the heart. Circulation 2007;116:1725-1735.10.1161\/CIRCULATIONAHA.106.67832617923583","DOI":"10.1161\/CIRCULATIONAHA.106.678326"},{"key":"2026070712454808900_ref45","doi-asserted-by":"crossref","unstructured":"Escobar-Morreale HF, Obregon MJ, Escobar del Rey F, Morreale de Escobar G: Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats. J Clin Invest 1995;96:2828-2838.10.1172\/JCI1183538675653","DOI":"10.1172\/JCI118353"},{"key":"2026070712454808900_ref46","doi-asserted-by":"crossref","unstructured":"Biondi B, Fazio S, Carella C, Amato G, Cittadini A, Lupoli G, Sacca L, Bellastella A, Lombardi G: Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1993;77:334-338.10.1210\/jcem.77.2.83450378345037","DOI":"10.1210\/jcem.77.2.8345037"},{"key":"2026070712454808900_ref47","doi-asserted-by":"crossref","unstructured":"Smit JW, Eustatia-Rutten CF, Corssmit EP, Pereira AM, Frolich M, Bleeker GB, Holman ER, van der Wall EE, Romijn JA, Bax JJ: Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2005;90:6041-6047.10.1210\/jc.2005-062016131580","DOI":"10.1210\/jc.2005-0620"},{"key":"2026070712454808900_ref48","doi-asserted-by":"crossref","unstructured":"Abdulrahman RM, Delgado V, Hoftijzer HC, Ng AC, Ewe SH, Marsan NA, Holman ER, Hovens GC, Corssmit EP, Romijn JA, Bax JJ, Smit JW: Both exogenous subclinical hyperthyroidism and short-term overt hypothyroidism affect myocardial strain in patients with differentiated thyroid carcinoma. Thyroid 2011;21:471-476.10.1089\/thy.2010.031921417919","DOI":"10.1089\/thy.2010.0319"},{"key":"2026070712454808900_ref49","doi-asserted-by":"crossref","unstructured":"Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH: Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 2014;63:2751-2768.10.1016\/j.jacc.2014.01.07324703918","DOI":"10.1016\/j.jacc.2014.01.073"},{"key":"2026070712454808900_ref50","doi-asserted-by":"crossref","unstructured":"Shargorodsky M, Serov S, Gavish D, Leibovitz E, Harpaz D, Zimlichman R: Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma. Thyroid 2006;16:381-386.10.1089\/thy.2006.16.38116646685","DOI":"10.1089\/thy.2006.16.381"},{"key":"2026070712454808900_ref51","doi-asserted-by":"crossref","unstructured":"Horne MK 3rd, Singh KK, Rosenfeld KG, Wesley R, Skarulis MC, Merryman PK, Cullinane A, Costello R, Patterson A, Eggerman T, Bernstein DM, Pucino F, Csako G: Is thyroid hormone suppression therapy prothrombotic? J Clin Endocrinol Metab 2004;89:4469-4473.10.1210\/jc.2004-053615356049","DOI":"10.1210\/jc.2004-0536"},{"key":"2026070712454808900_ref52","doi-asserted-by":"crossref","unstructured":"Abonowara A, Quraishi A, Sapp JL, Alqambar MH, Saric A, O'Connell CM, Rajaraman MM, Hart RD, Imran SA: Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer. Clin Invest Med 2012;35:E152-E156.22673318","DOI":"10.25011\/cim.v35i3.16591"},{"key":"2026070712454808900_ref53","doi-asserted-by":"crossref","unstructured":"Wang L, Smith AW, Palmer FL, Tuttle RM M, Mahrous A, Nixon IJ, Patel SG, Ganly I, Fagin JA, Boucai L: TSH suppression increases the risk of osteoporosis without decreasing recurrence in ATA low and intermediate risk patients with differentiated thyroid carcinoma. Thyroid 2015;25:300-307.10.1089\/thy.2014.028725386760","DOI":"10.1089\/thy.2014.0287"},{"key":"2026070712454808900_ref54","doi-asserted-by":"crossref","unstructured":"Klein Hesselink EN, Klein Hesselink MS, de Bock GH, Gansevoort RT, Bakker SJ, Vredeveld EJ, van der Horst-Schrivers AN, van der Horst IC, Kamphuisen PW, Plukker JT, Links TP, Lefrandt JD: Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J Clin Oncol 2013;31:4046-4053.10.1200\/JCO.2013.49.104324101052","DOI":"10.1200\/JCO.2013.49.1043"},{"key":"2026070712454808900_ref55","doi-asserted-by":"crossref","unstructured":"Bassett JH, Williams GR: Critical role of the hypothalamic-pituitary-thyroid axis in bone. Bone 2008;43:418-426.10.1016\/j.bone.2008.05.00718585995","DOI":"10.1016\/j.bone.2008.05.007"},{"key":"2026070712454808900_ref56","doi-asserted-by":"crossref","unstructured":"Bassett JH, Williams GR: The skeletal phenotypes of TR\u03b1 and TR\u03b2 mutant mice. J Mol Endocrinol 2009;42:269-282.10.1677\/JME-08-014219114539","DOI":"10.1677\/JME-08-0142"},{"key":"2026070712454808900_ref57","doi-asserted-by":"crossref","unstructured":"O'Shea PJ, Harvey CB, Suzuki H, Kaneshige M, Kaneshige K, Cheng SY, Williams GR: A thyrotoxic skeletal phenotype of advanced bone formation in mice with resistance to thyroid hormone. Mol Endocrinol 2003;17:1410-1424.10.1210\/me.2002-029612677005","DOI":"10.1210\/me.2002-0296"},{"key":"2026070712454808900_ref58","doi-asserted-by":"crossref","unstructured":"O'Shea PJ, Bassett JH, Sriskantharajah S, Ying H, Cheng SY, Williams GR: Contrasting skeletal phenotypes in mice with an identical mutation targeted to thyroid hormone receptor \u03b11 or \u03b2. Mol Endocrinol 2005;19:3045-3059.10.1210\/me.2005-022416051666","DOI":"10.1210\/me.2005-0224"},{"key":"2026070712454808900_ref59","doi-asserted-by":"crossref","unstructured":"Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M: TSH is a negative regulator of skeletal remodeling. Cell 2003;115:151-162.10.1016\/S0092-8674(03)00771-214567913","DOI":"10.1016\/S0092-8674(03)00771-2"},{"key":"2026070712454808900_ref60","doi-asserted-by":"crossref","unstructured":"Verburg FA, Smit JW, Grelle I, Visser TJ, Peeters RP, Reiners C: Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy. Clin Endocrinol 2012;76:577-581.10.1111\/j.1365-2265.2011.04262.x22017394","DOI":"10.1111\/j.1365-2265.2011.04262.x"},{"key":"2026070712454808900_ref61","doi-asserted-by":"crossref","unstructured":"Sugitani I, Fujimoto Y: Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery 2011;150:1250-1257.10.1016\/j.surg.2011.09.01322136848","DOI":"10.1016\/j.surg.2011.09.013"},{"key":"2026070712454808900_ref62","doi-asserted-by":"crossref","unstructured":"Kim MK, Yun KJ, Kim MH, Lim DJ, Kwon HS, Song KH, Kang MI, Baek KH: The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Bone 2015;71:101-105.10.1016\/j.bone.2014.10.00925445448","DOI":"10.1016\/j.bone.2014.10.009"},{"key":"2026070712454808900_ref63","doi-asserted-by":"crossref","unstructured":"Tournis S, Antoniou JD, Liakou CG, Christodoulou J, Papakitsou E, Galanos A, Makris K, Marketos H, Nikopoulou S, Tzavara I, Triantafyllopoulos IK, Dontas I, Papaioannou N, Lyritis GP, Alevizaki M: Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression. Clin Endocrinol 2015;82:197-204.10.1111\/cen.1256025040693","DOI":"10.1111\/cen.12560"},{"key":"2026070712454808900_ref64","doi-asserted-by":"crossref","unstructured":"Reverter JL, Colome E, Holgado S, Aguilera E, Soldevila B, Mateo L, Sanmarti A: Bone mineral density and bone fracture in male patients receiving long-term suppressive levothyroxine treatment for differentiated thyroid carcinoma. Endocrine 2010;37:467-472.10.1007\/s12020-010-9339-z20960170","DOI":"10.1007\/s12020-010-9339-z"},{"key":"2026070712454808900_ref65","doi-asserted-by":"crossref","unstructured":"Schneider R, Schneider M, Reiners C, Schneider P: Effects of levothyroxine on bone mineral density, muscle force, and bone turnover markers: a cohort study. J Clin Endocrinol Metab 2012;97:3926-3934.10.1210\/jc.2012-257022977269","DOI":"10.1210\/jc.2012-2570"},{"key":"2026070712454808900_ref66","doi-asserted-by":"crossref","unstructured":"Quan ML, Pasieka JL, Rorstad O: Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature. J Surg Oncol 2002;79:62-69.10.1002\/jso.1004311754378","DOI":"10.1002\/jso.10043"},{"key":"2026070712454808900_ref67","doi-asserted-by":"crossref","unstructured":"Franklyn JA, Betteridge J, Daykin J, Holder R, Oates GD, Parle JV, Lilley J, Heath DA, Sheppard MC: Long-term thyroxine treatment and bone mineral density. Lancet 1992;340:9-13.10.1016\/0140-6736(92)92423-D1351654","DOI":"10.1016\/0140-6736(92)92423-D"},{"key":"2026070712454808900_ref68","unstructured":"Heijckmann AC, Huijberts MS, Geusens P, de Vries J, Menheere PP, Wolffenbuttel BH: Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive &lt;span style=\"font-variant:small-caps; text-transform:lowercase\"&gt;L&lt;\/span&gt;-thyroxine therapy for differentiated thyroid carcinoma. Eur J Endocrinol 2005;153:23-29.10.1530\/eje.1.0193315994742"},{"key":"2026070712454808900_ref69","doi-asserted-by":"crossref","unstructured":"Takamura Y, Miyauchi A, Yabuta T, Kihara M, Ito Y, Miya A: Attenuation of postmenopausal bone loss in patients with transient hypoparathyroidism after total thyroidectomy. World J Surg 2013;37:2860-2865.10.1007\/s00268-013-2207-224045966","DOI":"10.1007\/s00268-013-2207-2"},{"key":"2026070712454808900_ref70","doi-asserted-by":"crossref","unstructured":"Kung AW, Yeung SS: Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J Clin Endocrinol Metab 1996;81:1232-1236.10.1210\/jcem.81.3.87726048772604","DOI":"10.1210\/jcem.81.3.8772604"},{"key":"2026070712454808900_ref71","doi-asserted-by":"crossref","unstructured":"Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, Ferguson L, Chen V, Lee K, Greenspan SL: Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab 1998;83:2324-2330.10.1210\/jcem.83.7.47829661603","DOI":"10.1210\/jc.83.7.2324"},{"key":"2026070712454808900_ref72","doi-asserted-by":"crossref","unstructured":"Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT, Page CP: Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine 1977;56:171-196.10.1097\/00005792-197705000-00001859443","DOI":"10.1097\/00005792-197705000-00001"},{"key":"2026070712454808900_ref73","doi-asserted-by":"crossref","unstructured":"Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C: Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996;81:4318-4323.10.1210\/jc.81.12.43188954034","DOI":"10.1210\/jcem.81.12.8954034"},{"key":"2026070712454808900_ref74","doi-asserted-by":"crossref","unstructured":"Sugitani I, Fujimoto Y: Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial. J Clin Endocrinol Metab 2010;95:4576-4583.10.1210\/jc.2010-016120660039","DOI":"10.1210\/jc.2010-0161"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/432397","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/4\/2\/82\/29128\/etj432397.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/4\/2\/82\/29128\/etj432397.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:03:37Z","timestamp":1783443817000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/4\/2\/82\/3970\/Radioiodine-Treatment-and-Thyroid-Hormone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,1]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,6,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000432397","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6,1]]}}}